EORTC Headquarters, Statistics Department, Brussels, Belgium.
J Biopharm Stat. 2020 Mar;30(2):305-321. doi: 10.1080/10543406.2019.1641817. Epub 2019 Jul 22.
This work focuses on the modification of two classical phase II trials designs, the A'Hern design, a single-arm single-stage design, and the Sargent and Goldberg design introduced in the context of flexible screening designs. In the first part of the paper, we have proposed a drift-adjusted A'Hern design, a hybrid design combining the A'Hern design and the Sargent and Goldberg design. Indeed, classical single-arm phase II designs such as the A'Hern design are still widely used in oncology. Conducting randomized comparative phase II trials may be challenging in many settings due to the increased sample size and this despite larger type 1 errors. Randomized non-comparative phase II designs first introduced by Herson and Carter include a simultaneous randomized standard-treatment reference arm to detect any drift in the reference arm assumption, but the trial is analyzed against historical controls as if it were a single-arm study. However, not incorporating at all an internal control arm in the trial design has been criticized in the literature. Our new design takes into account the observed response rate in a non-comparative reference arm to reduce the trial's risk of a false-positive conclusion. In the second part, we have proposed an alternative strategy to determining the sample size of the screened selection design. The latter, introduced in recent years by Yap et al. and Wu et al., extended the Sargent and Goldberg design to include a comparison to a historical control. However, their sample size computations may have potential weaknesses, which motivated us to revisit the existing approaches. A detailed simulation study has been carried out to evaluate the operating characteristics of the drift-adjusted A'Hern design and the different sample size strategies of the screened selection designs.
这项工作专注于对两种经典的二期临床试验设计的修改,即 A'Hern 设计,一种单臂单阶段设计,以及 Sargent 和 Goldberg 设计,它们是在灵活筛选设计的背景下引入的。在本文的第一部分,我们提出了一种漂移调整的 A'Hern 设计,一种混合设计,结合了 A'Hern 设计和 Sargent 和 Goldberg 设计。事实上,经典的单臂二期临床试验设计,如 A'Hern 设计,仍然在肿瘤学中广泛应用。在许多情况下,由于样本量的增加,进行随机对照二期临床试验可能具有挑战性,尽管这会导致更大的第一类错误。Herson 和 Carter 首次引入的随机非对照二期临床试验设计包括同时进行随机标准治疗参考臂,以检测参考臂假设中的任何漂移,但该试验是针对历史对照进行分析的,就好像它是一项单臂研究一样。然而,在试验设计中完全不纳入内部对照臂在文献中受到了批评。我们的新设计考虑了非对照参考臂中观察到的反应率,以降低试验得出假阳性结论的风险。在第二部分,我们提出了一种替代策略来确定筛选选择设计的样本量。后者由 Yap 等人和 Wu 等人近年来引入,将 Sargent 和 Goldberg 设计扩展到包括与历史对照的比较。然而,他们的样本量计算可能存在潜在的弱点,这促使我们重新审视现有的方法。进行了详细的模拟研究,以评估漂移调整的 A'Hern 设计和筛选选择设计的不同样本量策略的操作特性。